Vida Health Study Highlights Real-World Obesity Treatment Outcomes in More Than 10,000 Adults

Vida Health Reports 7.3% Average Weight Loss at 12 Months in Real-World Analysis of More Than 10,000 Adults

Vida Health, a digital health company providing integrated, longitudinal cardiometabolic and behavioral healthcare, has announced findings from a real-world analysis evaluating weight loss and cardiometabolic health outcomes among adults enrolled in its telehealth program. Presented at ObesityWeek 2026, the analysis included more than 10,000 adults across 30 employer organizations and found that participants with available 12-month weight measurements achieved an average weight reduction of 7.3%.

The findings offer insight into how comprehensive and individualized obesity care can support people across different treatment pathways. Rather than concentrating exclusively on patients with high-acuity needs or those meeting specific body mass index (BMI) thresholds, the analysis examined outcomes across Vida Health’s broader enrolled population. This approach was designed to provide a more representative picture of how members experience obesity treatment in a real-world healthcare setting.

The study evaluated three distinct treatment cohorts: individuals who were new to glucagon-like peptide-1 (GLP-1) therapy and initiated treatment through Vida, members who transferred their existing GLP-1 care to the company, and individuals receiving behavioral support alone or alongside non-GLP-1 medications.

Average weight loss varied across the three groups, but each demonstrated meaningful reductions over the 12-month observation period. Members new to GLP-1 therapy achieved an average weight loss of 10.0%, while those transferring their existing GLP-1 treatment achieved 8.0%. Members receiving behavioral care or non-GLP-1 medication-based treatment recorded an average weight reduction of 5.5%.

In addition to changes in body weight, the analysis identified improvements in several cardiometabolic measurements, including triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, high-density lipoprotein (HDL) cholesterol and glycated hemoglobin (HbA1c). These findings highlight the importance of evaluating obesity treatment through a broader health perspective rather than relying exclusively on weight reduction.

Evaluating Obesity Care Across a Broad Employer Population

The retrospective analysis included adults enrolled in Vida Health’s telehealth program between January 2024 and September 2025. A total of 10,019 adults were included in the overall analysis, representing members from 30 employer organizations.

Of these participants, 4,944 had available weight measurements at the 12-month assessment point. Across this group, the average total body weight reduction was 7.3%.

One of the important characteristics of the analysis was its focus on the company’s total enrolled population rather than a narrowly selected group of patients. Some clinical trials concentrate on individuals with higher BMI levels, more complex medical needs or specific treatment characteristics. Vida’s analysis instead sought to capture the experiences of a wider range of adults participating in its obesity care program.

The study also measured weight changes from the date of enrollment rather than beginning the observation period when members reached the full dosage of a GLP-1 medication. This distinction is important because people do not necessarily begin medication immediately after entering a healthcare program. Treatment initiation, medication adjustments and dosage titration can take time, depending on individual circumstances and clinical considerations.

By using enrollment as the starting point, the analysis incorporated the different stages of treatment that members experienced during their first year of care. This included individuals who began medication later in their treatment journey, those who increased their dosage gradually, and members who temporarily paused medication.

The approach provides a more practical understanding of outcomes across an employer population because it reflects the way obesity care is delivered and experienced outside controlled clinical trial environments.

For employers and health plans, this type of evidence may help inform decisions about obesity management programs, particularly when evaluating the potential value of integrated care models that combine clinical treatment, behavioral support and ongoing health monitoring.

Weight Loss Outcomes Across Three Treatment Cohorts

The analysis separated participants into three treatment groups to examine how outcomes differed according to their care pathways. Each group achieved average weight reductions over the 12-month period.

New to GLP-1 therapy

Members who initiated GLP-1 treatment through Vida Health achieved an average total body weight reduction of 10.0%. This cohort included 850 participants with available 12-month weight data.

GLP-1 medications have become an important treatment option for obesity and related metabolic conditions. However, medication initiation and dosage adjustments can vary between individuals. The results from this cohort reflect outcomes measured from enrollment, including the time members required to begin treatment and progress through medication titration.

Transfer of GLP-1 care

Participants who joined Vida Health while already receiving GLP-1 therapy and continued treatment achieved an average weight reduction of 8.0%. This group included 2,112 members with 12-month measurements.

The findings provide information about outcomes among individuals who were already taking GLP-1 medication before transferring their care to Vida. Their inclusion is relevant because real-world obesity programs frequently serve people at different points in their treatment journeys, rather than exclusively supporting individuals starting medication for the first time.

Behavioral and non-GLP-1 care

Members receiving behavioral care alone or in combination with a non-GLP-1 medication achieved an average weight reduction of 5.5%. This cohort included 1,982 participants with available 12-month weight data.

The results demonstrate that weight reduction was also observed among members whose treatment pathways did not involve GLP-1 medication. Behavioral support and other medication options can form part of an individualized obesity management strategy, depending on a person’s health needs and treatment considerations.

Together, the three cohorts illustrate the range of approaches represented in Vida Health’s program. The findings also suggest that outcomes should be considered in the context of the treatment pathway and the individual circumstances of each member.

Improvements in Cardiometabolic Health Measures

Beyond weight reduction, Vida Health’s analysis examined changes in several cardiometabolic indicators over 12 months. These measurements provide additional information about changes in metabolic health and help assess treatment outcomes beyond body weight alone.

The analysis reported reductions in triglycerides, total cholesterol, LDL cholesterol, glucose and HbA1c, alongside an increase in HDL cholesterol.

The key changes included:

  • Triglycerides: Average reduction of 16.5 mg/dL.
  • Total cholesterol: Average reduction of 6.1 mg/dL.
  • LDL cholesterol: Average reduction of 5.2 mg/dL.
  • Glucose: Average reduction of 3.8 mg/dL.
  • HDL cholesterol: Average increase of 1.9 mg/dL.
  • HbA1c: Average reduction of 0.21 percentage points.

Triglycerides and cholesterol are important indicators of cardiovascular and metabolic health. Elevated triglyceride and LDL cholesterol levels can be associated with increased cardiovascular risk, while HDL cholesterol is commonly monitored as part of a broader lipid profile.

Glucose and HbA1c measurements provide information about blood sugar regulation. HbA1c reflects average blood glucose levels over an extended period and is frequently used to assess longer-term glycemic control.

The observed reductions in glucose and HbA1c, together with improvements in lipid measurements, add another dimension to the study’s findings. They indicate that the outcomes evaluated by Vida extended beyond changes in body weight and included several measures associated with cardiometabolic health.

The company emphasized that obesity is a complex, long-term health condition influenced by multiple factors. Consequently, treatment strategies may need to address medication use, behavioral patterns and other aspects of a person’s health rather than focusing on a single intervention.

Importance of Measuring Outcomes From the Start of Care

A central feature of the study was its decision to measure progress from the moment members enrolled in the program. This differs from approaches that begin tracking outcomes only after a participant starts medication or reaches a target dosage.

In everyday healthcare settings, treatment does not always follow a uniform timeline. Some individuals may require additional consultations before starting medication, while others may need gradual dosage increases to support treatment tolerability. Some patients may also pause or change their medication during the course of care.

These factors can influence the results reported in real-world populations. Measuring outcomes from enrollment captures these experiences and provides a broader view of what members achieve during their first year in a healthcare program.

The methodology also has potential relevance for organizations responsible for employee healthcare benefits. Employers and health plans need to understand not only the outcomes experienced by people who complete a particular medication pathway but also the results achieved across the full population entering care.

By including different treatment experiences, the analysis offers a perspective on how an integrated obesity care program may perform across a workforce with varied clinical needs and treatment preferences.

The findings also reinforce the value of tracking multiple health indicators. Weight reduction remains an important measure in obesity management, but improvements in blood sugar and cholesterol can provide additional information about changes in overall cardiometabolic health.

Vida Health Emphasizes Individualized and Integrated Treatment

Richard Frank, MD, Chief Medical Officer at Vida Health, said the results demonstrate the potential of comprehensive obesity care to support improvements across an employer’s broader workforce.

He explained that employers should not rely exclusively on the outcomes that medications may achieve under ideal clinical conditions when evaluating obesity treatment programs. Instead, the findings suggest that meaningful outcomes can be observed across different treatment pathways and stages of care.

Frank also highlighted the importance of understanding results in real-world populations. According to him, a broader view of treatment outcomes can help employers make more informed decisions about how to support members while managing the long-term costs associated with obesity.

His comments reflect a broader shift toward evaluating obesity care through integrated treatment models. Although GLP-1 medications are an important part of the current obesity treatment landscape, medication alone may not address every factor influencing an individual’s health.

A comprehensive approach can incorporate clinical guidance, behavioral interventions and ongoing support to help members navigate treatment decisions over time. Such models may also provide flexibility for people who are not taking GLP-1 medications or who require different approaches to weight management.

Aarathi Venkatesan, PhD, Senior Vice President of Business Intelligence and Health Analytics at Vida Health and lead author of the study, emphasized that cardiometabolic health management requires more than prescribing medication.

Venkatesan said the study was designed to measure progress beginning when members entered care, allowing researchers to account for the time required to initiate and adjust medication therapies. She also explained that the analysis examined blood sugar and cholesterol changes alongside weight reduction to provide a more complete picture of treatment outcomes.

This broader evaluation is particularly relevant because obesity and cardiometabolic conditions can involve several interconnected health factors. Assessing multiple indicators can help healthcare organizations better understand how different treatment strategies relate to changes in members’ health over time.

Implications for Employers and Health Plans

The findings may be relevant to employers and health plans seeking to develop or evaluate obesity management benefits. As demand for obesity treatments continues to grow, organizations face decisions about how to provide access to effective care while managing healthcare spending and supporting employees with different clinical needs.

A program that evaluates outcomes across a broad enrolled population can offer information that may be useful when assessing the performance of employer-sponsored healthcare initiatives. It can also help organizations consider how treatment pathways, medication use and behavioral support contribute to outcomes.

The study’s inclusion of members who were new to GLP-1 therapy, already receiving GLP-1 treatment or following non-GLP-1 approaches provides a more varied view of the population participating in obesity care.

However, the findings represent a retrospective real-world analysis and should be interpreted in the context of the study design. The results describe outcomes among Vida Health program participants with available measurements and do not establish that the program or any individual treatment approach caused all observed changes. The analysis also does not demonstrate that every member achieved the average reported outcome.

Nevertheless, the results contribute to the growing body of real-world evidence examining how obesity care is delivered beyond clinical trial settings. They underscore the importance of evaluating treatment from the beginning of care and considering multiple health outcomes when assessing progress.

Advancing a Broader Approach to Obesity Management

Vida Health’s ObesityWeek 2026 presentation highlights the potential value of individualized, integrated obesity care across a diverse employer population. The analysis included 10,019 adults enrolled between January 2024 and September 2025, with 4,944 participants contributing 12-month weight data. These members achieved an average total body weight reduction of 7.3%.

Results were observed across all three treatment cohorts, including members starting GLP-1 therapy, transferring existing GLP-1 care and receiving behavioral or non-GLP-1 medication-based treatment. Improvements in triglycerides, cholesterol, glucose and HbA1c further expanded the assessment beyond weight loss alone.

By examining outcomes from enrollment rather than from the point of full medication dosage, Vida Health sought to reflect the realities of obesity treatment in everyday clinical practice. The findings provide employers and health plans with additional information about outcomes across a broader population and highlight the role of comprehensive care in supporting long-term cardiometabolic health.

As healthcare organizations continue to evaluate approaches to obesity management, real-world evidence such as this may help inform decisions about treatment access, individualized care strategies and the measurement of health outcomes across employee populations.

About Vida Health

Vida Health is a value-based, virtual cardiometabolic care provider that matches members to the right level of care based on their metabolic instability. Its medication guidance system prioritizes lower-cost, high-value therapeutic alternatives across obesity, diabetes, hypertension, hyperlipidemia, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea (OSA), and chronic obstructive pulmonary disease (COPD).

Vida serves members at all acuity levels, combining evidence-based prescribing with behavior change support and provider-led care. The company’s multidisciplinary team of obesity medicine-certified physicians, nurses, registered dietitians, expert coaches, and licensed therapists delivers a whole-person approach that improves outcomes while reducing avoidable healthcare costs. Vida serves members in all 50 states and Washington, D.C., offers services in both English and Spanish, and operates on a value-based pricing model that centers on measurable health outcomes. 

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter